Skip Navigation
Home
Browse Guidelines
Expert Commentaries
Guideline Syntheses
Guideline Matrix
Guideline Resources
Compare Guidelines
Frequently Asked Questions
Submit Guidelines
About
myNGC

Announcements

January 28, 2013

New My NGC Tutorial Video


View the new My NGC Tutorial on how to use the active and passive personalization features on the NGC Web site.

Health Awareness Topics - January 2013



Conference News


  • The Guidelines International Network North America (G-I-N NA) continues to sponsor a monthly webinar series on topics of interest to the North American guideline community. Information on upcoming webinars, as well as audio files and slides from past webinars, is available on the G-I-N Web site External Web Site Policy.

U.S. Food and Drug Administration (FDA) Advisory


  • January 25, 2013: Samsca (tolvaptan) External Web Site Policy: Otsuka and FDA notified healthcare professionals of significant liver injury associated with the use of Samsca. Findings indicate that Samsca (tolvaptan) has the potential to cause irreversible and potentially fatal liver injury. Healthcare providers should perform liver tests promptly in patients who report symptoms that may indicate liver injury, including fatigue, anorexia, right upper abdominal discomfort, dark urine or jaundice. If hepatic injury is suspected, Samsca should be promptly discontinued, appropriate treatment should be instituted, and investigations should be performed to determine probable cause.

NGC's Sister Resources